tetano
Editor, Senior Moderator
CEL-SCI Corporation (NYSE Amex: CVM) today announced the positive results of efficacy studies in mice of L.E.A.P.S.TM (Ligand Epitope Antigen Presentation System) H1N1 activated dendritic cells (DCs) to treat the H1N1 virus. Scientists found that H1N1-infected mice treated with LEAPS-H1N1 DCs showed a survival advantage over mice treated with control DCs. The work was performed in collaboration with scientists led by Kanta Subbarao, M.B.B.S., M.P.H, of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, USA. The study results were announced during the Keystone Conference on "Pathogenesis of Influenza: Virus-Host Interactions" in Hong Kong, China.
An important observation made in this study was that the LEAPS H1N1-activated DCs were drawn to and concentrated at the lungs, where they were most needed to combat the infecting virus, and were not dissipated throughout the body. Control DCs (DCs not pre-activated with LEAPS) did not localize to the lungs of the infected mice. In a different model, it was shown that LEAPS-activated DCs do not cause secretion of the type of inflammatory cytokines usually associated with "cytokine storm". Thus this treatment may be useful in the treatment of influenza-infected individuals. The specific and selective behavior of LEAPS-activated DCs could be used in the treatment and mitigation of many other infectious diseases such as pandemic viruses and even cancer and autoimmune conditions.
http://www.medicalnewstoday.com/releases/226776.php
An important observation made in this study was that the LEAPS H1N1-activated DCs were drawn to and concentrated at the lungs, where they were most needed to combat the infecting virus, and were not dissipated throughout the body. Control DCs (DCs not pre-activated with LEAPS) did not localize to the lungs of the infected mice. In a different model, it was shown that LEAPS-activated DCs do not cause secretion of the type of inflammatory cytokines usually associated with "cytokine storm". Thus this treatment may be useful in the treatment of influenza-infected individuals. The specific and selective behavior of LEAPS-activated DCs could be used in the treatment and mitigation of many other infectious diseases such as pandemic viruses and even cancer and autoimmune conditions.
http://www.medicalnewstoday.com/releases/226776.php